FDA information describes slowing of decline, not guaranteed improvement. Discuss diarrhea/GI symptoms, platelet counts, triglycerides and QT risk, plus the clinic's laboratory and dose-adjustment plan.
What this means in real life
Duvyzat (givinostat) is an oral histone deacetylase inhibitor approved by the FDA for DMD in patients age 6 years and older. In the pivotal study, the main finding was a slower decline on a timed functional measure compared with placebo; it should not be presented as a cure or a guarantee of visible improvement. It is used alongside corticosteroids in the studied population, and the prescriber should explain how the evidence maps to the individual.
Important safety and monitoring issues include diarrhea and other gastrointestinal symptoms, reduced platelet counts, increased triglycerides and QT prolongation risk. The current label includes baseline and follow-up laboratory and cardiac considerations, dose adjustment and interruption rules, and drug-interaction guidance. Body weight affects dosing.
Before starting, review all medicines and supplements, cardiac rhythm history, blood counts, triglycerides and GI history. Ask exactly when labs will be checked and which result or symptom should trigger a call, dose change or pause.
A practical checklist
- ✓
Confirm age, indication and current corticosteroid plan with a DMD prescriber.
- ✓
Complete label-directed baseline blood count, triglyceride and QT/medication review.
- ✓
Get a written laboratory schedule and dose-adjustment thresholds.
- ✓
Track diarrhea, vomiting, hydration and missed doses.
- ✓
Reassess benefit, burden and adherence using agreed functional measures.
Questions to bring with you
Use these at the clinic, school meeting, equipment evaluation, program interview or benefits call. Write down the answers and who owns the next step.
- What benefit did the trial demonstrate, and what did it not prove?
- Which baseline results could delay or prevent treatment?
- Which medicines or supplements increase QT or other risks?
- How are GI effects and low platelets managed?
- What would make us continue, adjust or stop treatment?
Important safety note
This topic can involve serious or immediate risk. Do not start, stop or change treatment from an online answer. Contact the Duchenne care team; use emergency services for urgent symptoms or danger.
Sources used for this guide
Direct links are included so families can check the original guidance and bring it to qualified professionals.
Content review: July 18, 2026. Medical labels, trials, benefits and programs can change after publication.
Did this article answer the question?
A thumbs-down sends the article to the private administrator dashboard for review.